Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2010 1
2011 1
2012 4
2013 3
2014 3
2015 2
2016 7
2017 2
2018 1
2019 4
2020 2
2021 7
2022 9
2023 13
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Jastreboff AM, et al. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. N Engl J Med. 2022. PMID: 35658024 Clinical Trial.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Jastreboff AM, et al. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26. N Engl J Med. 2023. PMID: 37366315 Clinical Trial.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Garvey WT, et al. Among authors: jastreboff am. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385275 Clinical Trial.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. Garvey WT, et al. Among authors: jastreboff am. Endocr Pract. 2016 Jul;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL. Epub 2016 May 24. Endocr Pract. 2016. PMID: 27219496
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Rosenstock J, et al. Among authors: jastreboff am. Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385280 Clinical Trial.
"The Times They Are A-Changin'" at Diabetes Care.
Kahn SE, Anderson CAM, Buse JB, Selvin E, Angell SY, Aroda VR, Castle JR, Cheng AYY, Danne T, Echouffo-Tcheugui JB, Florez JC, Gadgil MD, Gastaldelli A, Green JB, Jastreboff AM, Kanaya AM, Kandula NR, Kovesdy CP, Laiteerapong N, Nadeau KJ, Pop-Busui R, Powe CE, Rebholz CM, Rickels MR, Sattar N, Shaw JE, Sims EK, Utzschneider KM, Vella A, Zhang C. Kahn SE, et al. Among authors: jastreboff am. Diabetes Care. 2023 Jan 1;46(1):3-5. doi: 10.2337/dci22-0045. Diabetes Care. 2023. PMID: 36548704 No abstract available.
Treating the Chronic Disease of Obesity.
Gossmann M, Butsch WS, Jastreboff AM. Gossmann M, et al. Among authors: jastreboff am. Med Clin North Am. 2021 Nov;105(6):983-1016. doi: 10.1016/j.mcna.2021.06.005. Med Clin North Am. 2021. PMID: 34688422 Review.
54 results